Development of a core outcome set for basal cell carcinoma

Daniel I Schlessinger; Kelly A Reynolds; McKenzie A Dirr; Sarah A Ibrahim; Arianna F Yanes; Jake M Lazaroff; Victoria Godinez-Puig; Brian R Chen; Anastasia O Kurta; Jill K Cotseones; Sarah G Chiren; Karina C Furlan; Sanjana Iyengar; Ramona Behshad; Danielle M DeHoratius; Pablo Denes; Aaron M Drucker; Leonard M Dzubow; Jeremy R Etzkorn; Catherine A Harwood; John Y S Kim; Naomi Lawrence; Erica H Lee; Gary S Lissner; Ashfaq A Marghoob; Rubeta N Matin; Adam R Mattox; Bharat B Mittal; J Regan Thomas; Xiaolong Alan Zhou; David Zloty; Jochen Schmitt; Jamie J Kirkham; April W Armstrong; Nicole Basset-Seguin; Elizabeth M Billingsley; Jeremy S Bordeaux; Jerry Brewer; Marc Brown; Mariah Brown; Scott A B Collins; Maria Concetta Fargnoli; Sergio Jobim De Azevedo; Reinhard Dummer; Alexander Eggermont; Glenn D Goldman; Merete Haedersdal; Elizabeth Hale; Allison Hanlon; Kelly L Harms; Conway C Huang; Eva A Hurst; Gino K In; Nicole Kelleners-Smeets; Meenal Kheterpal; Barry Leshin; Michel Mcdonald; Stanley J Miller; Alexander Miller; Eliot N Mostow; Myrto Trakatelli; Kishwer S Nehal; Desiree Ratner; Howard Rogers; Kavita Y Sarin; Seaver L Soon; Thomas Stasko; Paul A Storrs; Luca Tagliaferri; Allison T Vidimos; Sandra L Wong; Siegrid S Yu; Iris Zalaudek; Nathalie C Zeitouni; John A Zitelli; Emily Poon; Joseph F Sobanko; Todd V Cartee; Ian A Maher; Murad Alam

doi:10.1016/j.jaad.2022.04.059

Development of a core outcome set for basal cell carcinoma

Daniel I Schlessinger, Kelly A Reynolds, McKenzie A Dirr, Sarah A Ibrahim, Arianna F Yanes, Jake M Lazaroff, Victoria Godinez-Puig, Brian R Chen, Anastasia O Kurta, Jill K Cotseones, Sarah G Chiren, Karina C Furlan, Sanjana Iyengar, Ramona Behshad, Danielle M DeHoratius, Pablo Denes, Aaron M Drucker, Leonard M Dzubow, Jeremy R Etzkorn, Catherine A HarwoodJohn Y S Kim, Naomi Lawrence, Erica H Lee, Gary S Lissner, Ashfaq A Marghoob, Rubeta N Matin, Adam R Mattox, Bharat B Mittal, J Regan Thomas, Xiaolong Alan Zhou, David Zloty, Jochen Schmitt, Jamie J Kirkham, April W Armstrong, Nicole Basset-Seguin, Elizabeth M Billingsley, Jeremy S Bordeaux, Jerry Brewer, Marc Brown, Mariah Brown, Scott A B Collins, Maria Concetta Fargnoli, Sergio Jobim De Azevedo, Reinhard Dummer, Alexander Eggermont, Glenn D Goldman, Merete Haedersdal, Elizabeth Hale, Allison Hanlon, Kelly L Harms, Conway C Huang, Eva A Hurst, Gino K In, Nicole Kelleners-Smeets, Meenal Kheterpal, Barry Leshin, Michel Mcdonald, Stanley J Miller, Alexander Miller, Eliot N Mostow, Myrto Trakatelli, Kishwer S Nehal, Desiree Ratner, Howard Rogers, Kavita Y Sarin, Seaver L Soon, Thomas Stasko, Paul A Storrs, Luca Tagliaferri, Allison T Vidimos, Sandra L Wong, Siegrid S Yu, Iris Zalaudek, Nathalie C Zeitouni, John A Zitelli, Emily Poon, Joseph F Sobanko, Todd V Cartee, Ian A Maher, Murad Alam^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

BACKGROUND: There is variation in the outcomes reported in clinical studies of basal cell carcinoma (BCC). This can prevent effective meta-analyses to answer important clinical questions.

OBJECTIVE: To identify a recommended minimum set of core outcomes for BCC clinical trials.

METHODS: Patient and professional Delphi process to cull a long-list, culminating in a consensus meeting. To be provisionally accepted, outcomes needed to be deemed 'important' (score: 7-9, of maximum of 9) by 70% of each stakeholder group.

RESULTS: 235 candidate outcomes identified via a systematic literature review and survey of key stakeholders were reduced to 74 that were rated by 100 health care professionals and patients in two Delphi rounds. 27 outcomes were provisionally accepted. The final core set of 5 agreed-upon outcomes after the consensus meeting was: complete response; persistent or serious adverse events; recurrence-free survival; quality of life; and patient satisfaction, including with cosmetic outcome.

LIMITATIONS: English-speaking patients and professionals rated outcomes extracted from English-language studies.

CONCLUSIONS: A core outcome set (COS) for basal cell carcinoma has been developed. Use of relevant measures may improve the utility of clinical research and the quality of therapeutic guidance available to clinicians.

Original language	English
Pages (from-to)	573-581
Number of pages	9
Journal	Journal of the American Academy of Dermatology
Volume	87
Issue number	3
Early online date	9 May 2022
DOIs	https://doi.org/10.1016/j.jaad.2022.04.059
Publication status	Published - Sept 2022

Access to Document

10.1016/j.jaad.2022.04.059

Cite this

Schlessinger, D. I., Reynolds, K. A., Dirr, M. A., Ibrahim, S. A., Yanes, A. F., Lazaroff, J. M., Godinez-Puig, V., Chen, B. R., Kurta, A. O., Cotseones, J. K., Chiren, S. G., Furlan, K. C., Iyengar, S., Behshad, R., DeHoratius, D. M., Denes, P., Drucker, A. M., Dzubow, L. M., Etzkorn, J. R., ... Alam, M. (2022). Development of a core outcome set for basal cell carcinoma. Journal of the American Academy of Dermatology, 87(3), 573-581. https://doi.org/10.1016/j.jaad.2022.04.059

@article{59b14facb14c454d99491bc37d5c84a6,

title = "Development of a core outcome set for basal cell carcinoma",

abstract = "BACKGROUND: There is variation in the outcomes reported in clinical studies of basal cell carcinoma (BCC). This can prevent effective meta-analyses to answer important clinical questions.OBJECTIVE: To identify a recommended minimum set of core outcomes for BCC clinical trials.METHODS: Patient and professional Delphi process to cull a long-list, culminating in a consensus meeting. To be provisionally accepted, outcomes needed to be deemed 'important' (score: 7-9, of maximum of 9) by 70% of each stakeholder group.RESULTS: 235 candidate outcomes identified via a systematic literature review and survey of key stakeholders were reduced to 74 that were rated by 100 health care professionals and patients in two Delphi rounds. 27 outcomes were provisionally accepted. The final core set of 5 agreed-upon outcomes after the consensus meeting was: complete response; persistent or serious adverse events; recurrence-free survival; quality of life; and patient satisfaction, including with cosmetic outcome.LIMITATIONS: English-speaking patients and professionals rated outcomes extracted from English-language studies.CONCLUSIONS: A core outcome set (COS) for basal cell carcinoma has been developed. Use of relevant measures may improve the utility of clinical research and the quality of therapeutic guidance available to clinicians.",

author = "Schlessinger, {Daniel I} and Reynolds, {Kelly A} and Dirr, {McKenzie A} and Ibrahim, {Sarah A} and Yanes, {Arianna F} and Lazaroff, {Jake M} and Victoria Godinez-Puig and Chen, {Brian R} and Kurta, {Anastasia O} and Cotseones, {Jill K} and Chiren, {Sarah G} and Furlan, {Karina C} and Sanjana Iyengar and Ramona Behshad and DeHoratius, {Danielle M} and Pablo Denes and Drucker, {Aaron M} and Dzubow, {Leonard M} and Etzkorn, {Jeremy R} and Harwood, {Catherine A} and Kim, {John Y S} and Naomi Lawrence and Lee, {Erica H} and Lissner, {Gary S} and Marghoob, {Ashfaq A} and Matin, {Rubeta N} and Mattox, {Adam R} and Mittal, {Bharat B} and Thomas, {J Regan} and Zhou, {Xiaolong Alan} and David Zloty and Jochen Schmitt and Kirkham, {Jamie J} and Armstrong, {April W} and Nicole Basset-Seguin and Billingsley, {Elizabeth M} and Bordeaux, {Jeremy S} and Jerry Brewer and Marc Brown and Mariah Brown and Collins, {Scott A B} and Fargnoli, {Maria Concetta} and {De Azevedo}, {Sergio Jobim} and Reinhard Dummer and Alexander Eggermont and Goldman, {Glenn D} and Merete Haedersdal and Elizabeth Hale and Allison Hanlon and Harms, {Kelly L} and Huang, {Conway C} and Hurst, {Eva A} and In, {Gino K} and Nicole Kelleners-Smeets and Meenal Kheterpal and Barry Leshin and Michel Mcdonald and Miller, {Stanley J} and Alexander Miller and Mostow, {Eliot N} and Myrto Trakatelli and Nehal, {Kishwer S} and Desiree Ratner and Howard Rogers and Sarin, {Kavita Y} and Soon, {Seaver L} and Thomas Stasko and Storrs, {Paul A} and Luca Tagliaferri and Vidimos, {Allison T} and Wong, {Sandra L} and Yu, {Siegrid S} and Iris Zalaudek and Zeitouni, {Nathalie C} and Zitelli, {John A} and Emily Poon and Sobanko, {Joseph F} and Cartee, {Todd V} and Maher, {Ian A} and Murad Alam",

note = "Copyright {\textcopyright} 2022. Published by Elsevier Inc.",

year = "2022",

month = sep,

doi = "10.1016/j.jaad.2022.04.059",

language = "English",

volume = "87",

pages = "573--581",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "MOSBY-ELSEVIER",

number = "3",

}

Schlessinger, DI, Reynolds, KA, Dirr, MA, Ibrahim, SA, Yanes, AF, Lazaroff, JM, Godinez-Puig, V, Chen, BR, Kurta, AO, Cotseones, JK, Chiren, SG, Furlan, KC, Iyengar, S, Behshad, R, DeHoratius, DM, Denes, P, Drucker, AM, Dzubow, LM, Etzkorn, JR, Harwood, CA, Kim, JYS, Lawrence, N, Lee, EH, Lissner, GS, Marghoob, AA, Matin, RN, Mattox, AR, Mittal, BB, Thomas, JR, Zhou, XA, Zloty, D, Schmitt, J, Kirkham, JJ, Armstrong, AW, Basset-Seguin, N, Billingsley, EM, Bordeaux, JS, Brewer, J, Brown, M, Brown, M, Collins, SAB, Fargnoli, MC, De Azevedo, SJ, Dummer, R, Eggermont, A, Goldman, GD, Haedersdal, M, Hale, E, Hanlon, A, Harms, KL, Huang, CC, Hurst, EA, In, GK, Kelleners-Smeets, N, Kheterpal, M, Leshin, B, Mcdonald, M, Miller, SJ, Miller, A, Mostow, EN, Trakatelli, M, Nehal, KS, Ratner, D, Rogers, H, Sarin, KY, Soon, SL, Stasko, T, Storrs, PA, Tagliaferri, L, Vidimos, AT, Wong, SL, Yu, SS, Zalaudek, I, Zeitouni, NC, Zitelli, JA, Poon, E, Sobanko, JF, Cartee, TV, Maher, IA & Alam, M 2022, 'Development of a core outcome set for basal cell carcinoma', Journal of the American Academy of Dermatology, vol. 87, no. 3, pp. 573-581. https://doi.org/10.1016/j.jaad.2022.04.059

TY - JOUR

T1 - Development of a core outcome set for basal cell carcinoma

AU - Schlessinger, Daniel I

AU - Reynolds, Kelly A

AU - Dirr, McKenzie A

AU - Ibrahim, Sarah A

AU - Yanes, Arianna F

AU - Lazaroff, Jake M

AU - Godinez-Puig, Victoria

AU - Chen, Brian R

AU - Kurta, Anastasia O

AU - Cotseones, Jill K

AU - Chiren, Sarah G

AU - Furlan, Karina C

AU - Iyengar, Sanjana

AU - Behshad, Ramona

AU - DeHoratius, Danielle M

AU - Denes, Pablo

AU - Drucker, Aaron M

AU - Dzubow, Leonard M

AU - Etzkorn, Jeremy R

AU - Harwood, Catherine A

AU - Kim, John Y S

AU - Lawrence, Naomi

AU - Lee, Erica H

AU - Lissner, Gary S

AU - Marghoob, Ashfaq A

AU - Matin, Rubeta N

AU - Mattox, Adam R

AU - Mittal, Bharat B

AU - Thomas, J Regan

AU - Zhou, Xiaolong Alan

AU - Zloty, David

AU - Schmitt, Jochen

AU - Kirkham, Jamie J

AU - Armstrong, April W

AU - Basset-Seguin, Nicole

AU - Billingsley, Elizabeth M

AU - Bordeaux, Jeremy S

AU - Brewer, Jerry

AU - Brown, Marc

AU - Brown, Mariah

AU - Collins, Scott A B

AU - Fargnoli, Maria Concetta

AU - De Azevedo, Sergio Jobim

AU - Dummer, Reinhard

AU - Eggermont, Alexander

AU - Goldman, Glenn D

AU - Haedersdal, Merete

AU - Hale, Elizabeth

AU - Hanlon, Allison

AU - Harms, Kelly L

AU - Huang, Conway C

AU - Hurst, Eva A

AU - In, Gino K

AU - Kelleners-Smeets, Nicole

AU - Kheterpal, Meenal

AU - Leshin, Barry

AU - Mcdonald, Michel

AU - Miller, Stanley J

AU - Miller, Alexander

AU - Mostow, Eliot N

AU - Trakatelli, Myrto

AU - Nehal, Kishwer S

AU - Ratner, Desiree

AU - Rogers, Howard

AU - Sarin, Kavita Y

AU - Soon, Seaver L

AU - Stasko, Thomas

AU - Storrs, Paul A

AU - Tagliaferri, Luca

AU - Vidimos, Allison T

AU - Wong, Sandra L

AU - Yu, Siegrid S

AU - Zalaudek, Iris

AU - Zeitouni, Nathalie C

AU - Zitelli, John A

AU - Poon, Emily

AU - Sobanko, Joseph F

AU - Cartee, Todd V

AU - Maher, Ian A

AU - Alam, Murad

PY - 2022/9

Y1 - 2022/9

N2 - BACKGROUND: There is variation in the outcomes reported in clinical studies of basal cell carcinoma (BCC). This can prevent effective meta-analyses to answer important clinical questions.OBJECTIVE: To identify a recommended minimum set of core outcomes for BCC clinical trials.METHODS: Patient and professional Delphi process to cull a long-list, culminating in a consensus meeting. To be provisionally accepted, outcomes needed to be deemed 'important' (score: 7-9, of maximum of 9) by 70% of each stakeholder group.RESULTS: 235 candidate outcomes identified via a systematic literature review and survey of key stakeholders were reduced to 74 that were rated by 100 health care professionals and patients in two Delphi rounds. 27 outcomes were provisionally accepted. The final core set of 5 agreed-upon outcomes after the consensus meeting was: complete response; persistent or serious adverse events; recurrence-free survival; quality of life; and patient satisfaction, including with cosmetic outcome.LIMITATIONS: English-speaking patients and professionals rated outcomes extracted from English-language studies.CONCLUSIONS: A core outcome set (COS) for basal cell carcinoma has been developed. Use of relevant measures may improve the utility of clinical research and the quality of therapeutic guidance available to clinicians.

AB - BACKGROUND: There is variation in the outcomes reported in clinical studies of basal cell carcinoma (BCC). This can prevent effective meta-analyses to answer important clinical questions.OBJECTIVE: To identify a recommended minimum set of core outcomes for BCC clinical trials.METHODS: Patient and professional Delphi process to cull a long-list, culminating in a consensus meeting. To be provisionally accepted, outcomes needed to be deemed 'important' (score: 7-9, of maximum of 9) by 70% of each stakeholder group.RESULTS: 235 candidate outcomes identified via a systematic literature review and survey of key stakeholders were reduced to 74 that were rated by 100 health care professionals and patients in two Delphi rounds. 27 outcomes were provisionally accepted. The final core set of 5 agreed-upon outcomes after the consensus meeting was: complete response; persistent or serious adverse events; recurrence-free survival; quality of life; and patient satisfaction, including with cosmetic outcome.LIMITATIONS: English-speaking patients and professionals rated outcomes extracted from English-language studies.CONCLUSIONS: A core outcome set (COS) for basal cell carcinoma has been developed. Use of relevant measures may improve the utility of clinical research and the quality of therapeutic guidance available to clinicians.

U2 - 10.1016/j.jaad.2022.04.059

DO - 10.1016/j.jaad.2022.04.059

M3 - Article

C2 - 35551965

SN - 0190-9622

VL - 87

SP - 573

EP - 581

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 3

ER -